Portola Pharma (PTLA) Misses Q4 EPS by 11c

Portola Pharma (NASDAQ: PTLA) reported Q4 EPS of ($1.23), $0.11 worse than the analyst estimate of ($1.12). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $2.43 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)